InsidersTradesSigma
Follow the AbCellera Biologics Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, AbCellera Biologics Inc. has logged 74 public disclosures. Market capitalisation: €3.7bn. The latest transaction was filed on 24 August 2026 (Acquisition). Among the most active insiders: Thermopylae Holdings Ltd.. All data is free.
74
Insider Decl.
n/a
Thresholds
€28m
33 ops.
Buy Volume
€313m
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AbCellera Biologics Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$17.13.
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,912 of 29,064 companies
29.0
score / 100
Value23
Quality35
FCF yld-4.7%
Earn yld-4.0%
EV/EBITDA·
ROE-17%
Gross mgn38%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations74 total
53,613 shares@ US$10.64Common SharesSEC:0001628280-26-058684:0
Canonical exit: 22 Nov 2026 (T+90)
10,000 shares@ US$11.030.0032% mcap11.3% of flowCommon SharesSEC:0001834423-26-000008:0
Canonical exit: 16 Nov 2026 (T+90)
46,387 shares@ US$10.370.013% mcap6.1% of flowCommon SharesSEC:0001628280-26-057007:0
Canonical exit: 10 Nov 2026 (T+90)
37,200 shares@ US$10.320.0100% mcap1.2% of flowCommon SharesSEC:0001834411-26-000008:0
Canonical exit: 12 Nov 2026 (T+90)
50,000 shares0Common SharesSEC:0001628280-26-056653:0
250,000 shares@ US$0.190.0012% mcap0.1% of flowCommon SharesSEC:0001834411-26-000006:0
38,000 shares@ US$3.440.1% of flowCommon SharesSEC:0001834449-26-000004:0
Canonical exit: 28 May 2026 (T+90)
177,457 shares@ US$3.270.4% of flowCommon SharesSEC:0001834449-26-000002:0
Canonical exit: 27 May 2026 (T+90)
42,600 shares@ US$3.420.5% of flowCommon SharesSEC:0001834411-26-000004:0
Canonical exit: 28 May 2026 (T+90)
225,000 shares0Common SharesSEC:0001834449-25-000004:0
50,000 shares@ US$3.569220.6% of flowCommon SharesSEC:0001834423-25-000004:0
Canonical exit: 24 Feb 2026 (T+90)
343,631 shares@ US$2.160.3% of flowCommon SharesSEC:0001628280-25-012154:0
Canonical exit: 9 Jun 2025 (T+90)
25,000 shares@ US$2.307.7% of flowCommon SharesSEC:0001628280-25-011750:0
Canonical exit: 8 Jun 2025 (T+90)
60,000 shares@ US$2.342819.0% of flowCommon SharesSEC:0001628280-25-011254:0
Canonical exit: 4 Jun 2025 (T+90)
286,000 shares0Common SharesSEC:0001628280-24-050097:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001628280-24-049327:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001628280-24-041217:0
283,516 shares@ US$2.610.3% of flowCommon SharesSEC:0001628280-24-038829:0
Canonical exit: 27 Nov 2024 (T+90)
83,334 shares@ US$0.1880.0% of flowCommon SharesSEC:0001628280-24-029675:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001628280-24-026338:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001703057-24-000026:0
210,000 shares0Common SharesSEC:0001703057-23-000049:0
56,125 shares@ US$2.700.1% of flowCommon SharesSEC:0001703057-23-000044:0
20,000 shares@ US$4.6412.6% of flowCommon SharesSEC:0001703057-23-000042:0
Canonical exit: 4 Feb 2024 (T+90)
20,000 shares@ US$4.910.7% of flowCommon SharesSEC:0001703057-23-000032:0
Canonical exit: 21 Dec 2023 (T+90)
25 of 74 declarations
关于 AbCellera Biologics Inc.
AbCellera Biologics Inc. 是一家生物技术公司，在美国纳斯达克（NASDAQ）市场上市，股票代码为 ABCL。该公司专注于利用技术驱动的平台发现和开发基于抗体的药物，该平台结合了微流控、数据分析、B 细胞筛选和高通量发现工作流程，以更快、更高效地识别治疗候选药物。AbCellera 由 Carl Hansen 及其同事于 2012 年创立，其根源可追溯到不列颠哥伦比亚大学，其总部和核心研究业务位于加拿大温哥华，尽管其股票在美国公开市场交易。（[investors.abcellera.com](https://investors.abcellera.com/news/news-releases/2018/AbCellera-Celebrates-the-Opening-of-its-New-Research-Facility-and-Corporate-Headquarters/default.aspx?utm_source=openai)） AbCellera 的商业模式有两大支柱。首先，它与制药和生物技术合作伙伴开展合作抗体发现项目。其次，它正在建立一个内部专有资产管线，以在合作费用和里程碑经济效益之外创造更长期的价值。对于投资者而言，这种组合很重要：合作业务有助于验证平台并实现收入机会多元化，而内部管线则提供了嵌入式上行空间，如果一个或多个项目成功推进到开发阶段。该公司表示，自 2015 年以来，它已与 40 多个合作伙伴合作开展了 100 多个抗体项目，这突显了其平台的广度以及其在主要生命科学客户中建立的信誉。（[abcellera.com](https://www.abcellera.com/?utm_source=openai)） 在竞争方面，AbCellera 更多地是一家发现基础设施公司，而非商业药物销售商。其战略优势在于其专有的抗体发现引擎，该引擎旨在解决未满足的重大医疗需求领域，包括内分泌学、女性健康、免疫学、肿瘤学和相关治疗领域。这使得 ABCL 成为一个平台生物技术公司，而非经典的制药制造商：投资案例取决于科学执行、合作伙伴吸引力以及将发现能力转化为临床并最终商业资产的能力。这也意味着该公司承担着典型的生物技术风险特征，包括临床失败、漫长的开发时间表以及下游货币化的不确定性。（[investors.abcellera.com](https://investors.abcellera.com/news/news-releases/2026/AbCellera-Reports-Full-Year-2025-Business-Results/default.aspx?utm_source=openai)） 公司近期更新强调了其日益以临床为导向的业务。在其 2025 年全年业绩中，AbCellera 表示，截至年底，其可用流动资金约为 700 million 美元，为公司的战略发展提供了支持。管理层还将 2025 年描述为公司转型为临床阶段生物技术公司并扩大领导团队的一年。近期提及的著名项目之一是 ABCL635，该项目旨在治疗与更年期相关的中度至重度血管舒缩症状，这表明公司致力于将平台发现转化为切实的临床资产。对于市场参与者而言，AbCellera 最好被视为一家在美国纳斯达克上市的生物技术公司，拥有加拿大的运营基地、强大的资产负债表以及一个高度依赖于合作伙伴关系和内部管线开发执行的平台故事。（[investors.abcellera.com](https://investors.abcellera.com/news/news-releases/2026/AbCellera-Reports-Full-Year-2025-Business-Results/default.aspx?utm_source=openai)）
